Assembly Biosciences (NASDAQ:ASMB) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday, Zacks.com reports.
According to Zacks, “Assembly Biosciences, Inc. is a biopharmaceutical company. It develops therapies for infectious diseases and other disorders of the gastrointestinal (GI) system. Assembly’s product portfolio consists of two late stage assets: VEN 307 for relief from pain associated with anal fissures and VEN 308 for the treatment of fecal incontinence. The Company is also developing novel microbiome-based technology for targeted oral delivery of therapeutic bacteria, complex proteins, viral antigens and small molecules to treat intractable infectious diseases of the GI tract, such as C. difficile infections. Assembly Biosciences Inc., formerly known as Ventrus Biosciences, Inc., is based in New York. “
Other equities analysts have also recently issued reports about the company. William Blair restated a “buy” rating on shares of Assembly Biosciences in a research note on Tuesday, July 16th. Chardan Capital restated a “neutral” rating on shares of Assembly Biosciences in a research note on Thursday, September 19th. BidaskClub upgraded Assembly Biosciences from a “sell” rating to a “hold” rating in a research note on Tuesday. Finally, ValuEngine upgraded Assembly Biosciences from a “hold” rating to a “buy” rating in a research note on Thursday, August 8th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company has an average rating of “Buy” and an average target price of $32.50.
Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings data on Monday, August 5th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, beating the consensus estimate of ($1.13) by $0.41. Assembly Biosciences had a negative return on equity of 46.33% and a negative net margin of 622.25%. The business had revenue of $3.08 million for the quarter, compared to analysts’ expectations of $3.90 million. As a group, equities research analysts expect that Assembly Biosciences will post -3.72 EPS for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jennison Associates LLC raised its stake in Assembly Biosciences by 3.3% in the 2nd quarter. Jennison Associates LLC now owns 2,555,637 shares of the biopharmaceutical company’s stock valued at $34,476,000 after acquiring an additional 82,558 shares during the period. BlackRock Inc. raised its stake in Assembly Biosciences by 1.9% in the 2nd quarter. BlackRock Inc. now owns 1,773,321 shares of the biopharmaceutical company’s stock valued at $23,921,000 after acquiring an additional 33,328 shares during the period. Vanguard Group Inc. raised its stake in Assembly Biosciences by 13.6% in the 2nd quarter. Vanguard Group Inc. now owns 1,226,953 shares of the biopharmaceutical company’s stock valued at $16,552,000 after acquiring an additional 146,452 shares during the period. Janus Henderson Group PLC grew its holdings in Assembly Biosciences by 0.4% during the 2nd quarter. Janus Henderson Group PLC now owns 956,634 shares of the biopharmaceutical company’s stock valued at $12,905,000 after buying an additional 3,749 shares in the last quarter. Finally, Rock Springs Capital Management LP grew its holdings in Assembly Biosciences by 24.4% during the 2nd quarter. Rock Springs Capital Management LP now owns 560,000 shares of the biopharmaceutical company’s stock valued at $7,554,000 after buying an additional 110,000 shares in the last quarter. Institutional investors own 81.94% of the company’s stock.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with the microbiome.
Recommended Story: Strike Price
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.